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Summary A monoclonal antibody (H17E2) recognising both placental alkaline phosphatase (PLAP) and
testicular PLAP-like alkaline phosphatase was incorporated in a solid phase immunoassay. This was used to
measure levels of PLAP in 257 sera from 148 patients with germ cell neoplasms of the testis. High levels of
PLAP were found in all patients with active seminomas (mean 0.850.D.) compared to those in clinical
remission (mean 0.200.D.) (P<0.0001). More importantly, changing levels of PLAP correlated with the
course of disease in 79 samples from 33 patients with seminoma (P<0.0001). Elevated PLAP levels were also
noted in patients in remission who were smokers (mean 0.32O.D.) compared to non-smokers (mean
0.15 .D.) (P<0.001).
These data demonstrate that determination of PLAP levels using this sensitive immunoassay is an
important new adjunct in the monitoring of the response to treatment in patients with seminomaa.
Seminoma of testis is a neoplasm that often
responds favourably to treatment. Unfortunately,
and in contrast to other types of germ cell
neoplasia, until now there has been no consistently
useful serum marker for monitoring disease in
patients with seminoma (Lange et al., 1982;
Jeppsson et al., 1983). This has led to obvious
problems in the assessment of response to treatment
and the early detection of relapse.
We have previously shown (Epenetos et al., 1984)
that placental alkaline phosphatase (PLAP) as
detected by monoclonal antibody H17E2 (Travers
& Bodmer, 1984) is expressed on the surface
membrane of most testicular germ cell tumour cells.
H17E2 immunoassay of sera of patients with
testicular cancer as reported in the accompanying
paper (Tucker et al., 1985) showed elevated PLAP
levels in patients with seminoma. These obser-
vations prompted us to collect a larger series of
serum samples in order to obtain definitive data on
the value of PLAP assays. The current study tested
257 samples of sera from two Scottish centres and
from one London centre, using a sensitive immuno-
assay system incorporating the monoclonal anti-
body (H17E2). We have with these examined the
value of assaying placental alkaline phosphatase in




Two hundred and fifty-seven serum samples from
148 patients with histologically proven germ cell
tumours of the testis were collected from the
Western General Hospital and Royal Infirmary,
Edinburgh, Ninewells Hospital, Dundee and
Hammersmith Hospital, London. The mean ages of
the patients were 32, 36 and 41 years for malignant
teratomas, mixed tumours, and seminomas
respectively. Assessment of disease status was based
upon history, physical examination and standard
diagnostic imaging techniques.
Monoclonal antibody H17E2
This mouse IgGI immunoglobulin was raised
against purified plasma membranes of normal term
placenta. It precipitates placental alkaline phos-
phatase (PLAP) activity and a single band of
67,000 daltons consistent with the mol. wt of
placental alkaline phosphatase (Travers & Bodmer,
1984). It also reacts with the leucine inhabitable
form of alkaline phosphatase found at low levels in
the normal testis and which is cross reactive with
the placental enzyme (Harris, 1982). It does not
cross react with other non-placental forms of
alkaline phosphatase.
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Immunoassayfor PLAP
Sera received as coded samples were added to plate
wells containing adsorbed antibody H17E2. Sera
were previously frozen, and thawed only once prior
to testing. After incubation for 2h at room
temperature and further washing, the activity of the
enzyme localised by the solid phase antibody was
determined colorimetrically. Standard calibration
curves were constructed using pregnancy sera and
large numbers of normal and pregnancy sera had
been previously tested to establish the repro-
ducibility and lower limits of sensitivity of this test
(Tucker et al., 1985).
Measurement ofspecificity and sensitivity
Specificity and sensitivity are statistical indices of
the efficiency of a diagnostic test (Yerushalmy,
1947). Specificity indicates the capacity for correct
diagnosis in confirmed negative cases whilst
sensitivity indicates the capacity for correct
diagnosis in confirmed positive cases of the disease.
Thus, sensitivity is defined as the number of true
positive cases of the disease divided by the total
number of confirmed positive results for enzyme
presence, which is the sum of the positive plus false
negative cases. Specificity is defined as the number
of true negative cases of the disease divided by the
total number of confirmed negative assays, which is
the sum of true negative plus false positive cases of
the disease. For a perfect diagnostic test both of
these ratios should be 1. The number of patients
was taken into account when calculating specificity
and sensistivity.
Results
Results from 257 sera and 148 patients were
analysed using computer programmes available at
the ICRF. These included students and test
statistic. Table I lists the number of patients, their
histological diagnoses and numbers of sera
examined.
Table I Clinicopathological categories.
No. of No. of
Histological diagnoses patients sera
Seminoma 81 127
Malignant teratoma - undifferentiated 28 65
Malignant teratoma - intermediate 21 36
Malignant teratoma - trophoblastic 2 3
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Figure 1 Serum PLAP levels in patients with
seminoma in clinical remission and with active disease.
The dotted horizontal line shows an arbitrary normal
value of 0.2O.D. units.
Figure 1 shows PLAP levels in patients
previously treated for seminoma who had no
clinical evidence of disease at the time of analysis
(n=70 patients, 116 samples) compared with levels
in patients known to have active disease (n= 11
patients, 13 samples). Patients in clinical remission
had PLAP levels ranging from 0.03 to 1.4O.D.
with a mean of 0.200.D.+0.22s.d., whilst patients
with active disease had levels ranging from 0.33 to
1.870.D. with a mean value of 0.85O.D.+0.62s.d.
(P<0.0001 for this difference). All patients with
active disease had PLAP levels of greater than
0.3O.D. Figure 2 shows serial PLAP levels in
patients with seminoma before and after treatment.
Those in remission (n=26) had a mean PLAP value
of 0.14 .D. +0.10s.d. while those with active
disease (n=6) had a mean PLAP value of 0.95O.D.
+0.650.D. (P<0.0001). In one patient thought to
be in clinical remission, serial PLAP estimation
*:








Figure 2 Serial PLAP levels in patients with
seminoma with disease regression, in remission or
disease progression. The dotted horizontal line shows
an arbitrary normal value of 0.20.D. units. In the
patients with disease regression the first point indicates
PLAP levels measured before the onset of therapy.
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revealed a significant rise from 0.07 to 0.68O.D.
This patient was reviewed and was found to have
cervical lymphadenopathy. It is possible that in this
case a rise in PLAP elvel was predicting a clinical
relapse ofseminoma but no histological confirmation
was available.
In the 15 patients with mixed tumours, elevated
PLAP levels were found in the 6 patients with
active disease (mean PLAP value 0.56O.D.
+0.22s.d.) while the 9 patients in remission had
levels below 0.200.D. (mean value 0.180.D.
+0.05O.D.) (P<0.0001).
In the 51 patients with malignant teratoma,
PLAP levels did not correlate with disease status
[mean PLAP levels 0.23 O.D. +0.2 s.d. in patients in
complete clinical remission (n=42) and 0.26O.D.
+0.31 s.d. in patients with active disease (n=9)].
PLAP levels in patients previously treated for all
germ cell tumours in complete clinical remission
were analysed in relation to patients' smoking
habits. Smokers (n=39) had a mean PLAP value of
0.320.D.+0.27s.d. while non-smoker (n=70) had
a mean PLAP value of 0.150.D.+0.16s.d.
(P<0.0001).
Patients with seminoma and in complete
remission who were smokers (n=22) had a mean
PLAP value of 0.29 .D. +0.32s.d. while non-
smokers (n=40) had a mean PLAP value of
0.140.D.+0.18 s.d. (P <0.0001). This effect due to
smoking, however, was not detectable in patients
with clinically active seminoma (n=8) [mean PLAP
value for smokers 0.72O.D. +0.59 s.d. and for non-
smokers (n=2) 0.66O.D.], probably because the s.e.
were large.
The sensitivity of the test was found to be 100%
and the specificity was 84% based on an arbitrary
normal value of 0.20.D. or 87.6% with a higher
operationally normal value of 0.3O.D. These
normal values were empirically established levels
giving the best apparent cut-off between normal
levels in non-smokers and elevated levels in
smokers, and those with disease. The sensitivity
reflects false-negative rate whilst the specificity
reflects the test's false positive rate.
Discussion
This study demonstrates that measurement of
serum levels of placental alkaline phosphatase
(PLAP) is a potentially clinically important test for
monitoring the disease status of patients with
seminoma. This suggests that although PLAP is
expressed by all types of germ cell tumours of the
testis (Epenetos et al., 1984) only seminomatous
tumours actually release PLAP into the
bloodstream. Elevated levels of PLAP (above
0.20.D.) were associated with active seminoma and
a significant correlation was observed between
PLAP levels, disease progression (rising levels),
disease regression (falling levels), and the
achievement of clinical remission (PLAP level
within the normal range). It was also noted that 14
out of 100 samples from patients with seminoma
thought to be in clinical remission had PLAP levels
above 0.30.D. It is possible that some of these
patients may have a small number of viable
seminoma cells that are escaping clinical detection.
Alternatively, these elevated levels could be due to
smoking, as suggested by the fact that these
patients were smokers. Further follow-up will be
required to assess the significance of the increased
PLAP levels in these patients.
The detectable elevation of PLAP in smokers is
interesting. This may reflect increased "leakage" of
PLAP from normal lung pneumocytes or induction
of increased amounts of the enzyme in pneumocytes
which are known to express low levels of PLAP
(Goldstein et al., 1982) or, alternatively, it could be
due to an effect of smoking on testicular function
causing inappropriate release of the testicular form
of placental alkaline phosphatase (Maslow et al.,
1983). However, the effect of smoking was over-
ridden by the higher levels noted in patients with
active seminoma, so while it will not greatly impede
the interpretation of results in patients with
established disease, appropriate allowances will
have to be made in patients known to be smokers.
Thus, the main weakness of this new assay is that
an elevated level of PLAP in a patient suspected of
having active seminoma does not infalibly indicate
active disease. Cigarette smoking may account for
some, if not all, of the elevated levels occasionally
found in patients in clinical remission.
The main strength of the assay is its negative
predictive accuracy. No patient with clinically active
seminoma has had a normal PLAP level - there
have been no false negative results. This fact alone
should make measurement of serum PLAP an
important investigation in the management of
patients suspected of having seminoma.
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